Abstract
The promise of idiotype-based therapeutics has been disappointing forcing a new look at the concept and its potential to generate an effective approach for immunotherapy. Here, the idiotype network theory is revisited with regard to the development of efficacious anti-idiotype vaccines. The experience of polyclonal anti-Idiotype reagents in animal models as well as an understanding of the immune response in humans lends to the proposition that polyclonal anti-Idiotype vaccines will be more effective compared to monoclonal-based anti-Idiotype vaccines. This novel strategy can be adapted in Biotech-standard production of therapeutic antibodies.
Document Type
Review
Publication Date
4-12-2019
Digital Object Identifier (DOI)
https://doi.org/10.3389/fimmu.2019.00808
Repository Citation
Köhler, Heinz; Pashov, Anastas; and Kieber-Emmons, Thomas, "The Promise of Anti-Idiotype Revisited" (2019). Microbiology, Immunology, and Molecular Genetics Faculty Publications. 142.
https://uknowledge.uky.edu/microbio_facpub/142
Notes/Citation Information
Published in Frontiers in Immunology, v. 10, article 808, p. 1-7.
© 2019 Kohler, Pashov and Kieber-Emmons.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.